February 21, 2018

CRISPR Could End Sickle Cell Disease, but Signing Up Black Patients for Clinical Trials Will Be a Hard Sell

(STAT News) – The first attempts to use a groundbreaking gene-editing technology in people will likely target patients with sickle cell disease, a crippling inherited disorder that in the U.S. predominantly strikes African-Americans. That should be welcome news, after decades … Read More

Recommended Reading